Doximity rises on Q1 beat; buys Canadian AI-based clinical reference firm

3.74BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US26622P1075
CUSIP
26622P107
Sector
Healthcare
Industry
Health Information Services
Fiscal Year End
March
IPO date
-
Updated At
-
PE Ratio
20.88
PEG Ratio
0.59
Book Value
5.19
Dividend Share
-
Dividend Yield
-
Earnings Share
0.98
Wall Street Target Price
25.42
EPS Estimate Current Year
1.55
EPS Estimate Next Year
1.62
EPS Estimate Current Quarter
0.2824
EPS Estimate Next Quarter
0.3454
Most Recent Quarter
-
Revenue TTM
644,862,976
Gross Profit TTM
574,537,024
EBITDA
228,788,992
Profit Margin
30.40%
Return On Assets TTM
11.61%
Return On Equity TTM
19.28%
Revenue Per Share TTM
3.448
Qtly Revenue Growth YOY
5.10%
Diluted Eps TTM
0.98
Qtly Earnings Growth YOY
-69.00%
Trailing PE
20.88
Forward PE
14
Price Sales TTM
5.8021
Price Book MRQ
3.935
Enterprise Value Revenue
4
Enterprise Value EBITDA
13
159.50
4.14%71.50
3.85%122.67
3.84%5.21
3.58%48.90
2.20%67.92
1.08%0.90
0.00%31.13
-5.49%84.50
-0.13%50.07
-0.03%Doximity rises on Q1 beat; buys Canadian AI-based clinical reference firm
Earnings Results: Doximity stock plummets after forecast, heads lower than IPO price for first time
Doximity sets fiscal 2022 guidance ahead of consensus after strong earnings beat